Please assess the completion status of the following clinical trial:

Trial Title: Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with haemophilia B (baseline level of Factor IX less than or equal to 2%)~* History of at least 150 exposure days to any Factor IX products~* Body Mass Index (BMI) below 30.0 kg/m2 (inclusive)~Exclusion Criteria:~* History of Factor IX inhibitors~* Platelet count less than 50,000 platelets/microlitre (assessed by laboratory)~* Kidney or liver dysfunction~* Scheduled surgery requiring Factor IX replacement therapy, during the trial period

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 25U/kg (Type: EXPERIMENTAL): None
- 50U/kg (Type: EXPERIMENTAL): None
- 100U/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).